Treatment rationale and design of the RAMNITA study: A phase II study of the efficacy of docetaxel + ramucirumab for non–small cell lung cancer with brain metastasis

BACKGROUND: We described the treatment rationale and procedure for a phase II study of docetaxel plus ramucirumab for non–small cell lung cancer (NSCLC) patients with brain metastasis (RAMNITA study: University Information Network Clinical Trials Registry identification no. [UMIN]: 000024551). Combi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanimura, Keiko, Uchino, Junji, Tamiya, Nobuyo, Kaneko, Yoshiko, Yamada, Tadaaki, Yoshimura, Kenichi, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999517/
https://www.ncbi.nlm.nih.gov/pubmed/29879079
http://dx.doi.org/10.1097/MD.0000000000011084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999517/
https://www.ncbi.nlm.nih.gov/pubmed/29879079
http://dx.doi.org/10.1097/MD.0000000000011084

Ejemplares similares